Literature DB >> 29775428

Involvement of human monogenic cardiomyopathy genes in experimental polygenic cardiac hypertrophy.

P R Prestes1, F Z Marques1,2, G Lopez-Campos3,4, P Lewandowski5, L M D Delbridge6, F J Charchar1, S B Harrap6.   

Abstract

Hypertrophic cardiomyopathy thickens heart muscles, reducing functionality and increasing risk of cardiac disease and morbidity. Genetic factors are involved, but their contribution is poorly understood. We used the hypertrophic heart rat (HHR), a unique normotensive polygenic model of cardiac hypertrophy and heart failure, to investigate the role of genes associated with monogenic human cardiomyopathy. We selected 42 genes involved in monogenic human cardiomyopathies to study: 1) DNA variants, by sequencing the whole genome of 13-wk-old HHR and age-matched normal heart rat (NHR), its genetic control strain; 2) mRNA expression, by targeted RNA-sequencing in left ventricles of HHR and NHR at 5 ages (2 days old and 4, 13, 33, and 50 wk old) compared with human idiopathic dilated cardiomyopathy data; and 3) microRNA expression, with rat microRNA microarrays in left ventricles of 2-day-old HHR and age-matched NHR. We also investigated experimentally validated microRNA-mRNA interactions. Whole-genome sequencing revealed unique variants mostly located in noncoding regions of HHR and NHR. We found 29 genes differentially expressed in at least 1 age. Genes encoding desmoglein 2 ( Dsg2) and transthyretin ( Ttr) were significantly differentially expressed at all ages in the HHR, but only Ttr was also differentially expressed in human idiopathic cardiomyopathy. Lastly, only two microRNAs differentially expressed in the HHR were present in our comparison of validated microRNA-mRNA interactions. These two microRNAs interact with five of the genes studied. Our study shows that genes involved in monogenic forms of human cardiomyopathies may also influence polygenic forms of the disease.

Entities:  

Keywords:  DNA sequencing; cardiac hypertrophy; cardiomyopathy; gene expression; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29775428     DOI: 10.1152/physiolgenomics.00143.2017

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  3 in total

1.  Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension.

Authors:  Katja Grabowski; Laura Herlan; Anika Witten; Fatimunnisa Qadri; Andreas Eisenreich; Diana Lindner; Martin Schädlich; Angela Schulz; Jana Subrova; Ketaki Nitin Mhatre; Uwe Primessnig; Ralph Plehm; Sophie van Linthout; Felicitas Escher; Michael Bader; Monika Stoll; Dirk Westermann; Frank R Heinzel; Reinhold Kreutz
Journal:  Hypertens Res       Date:  2021-12-16       Impact factor: 3.872

2.  Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis.

Authors:  Antonella De Lillo; Gita A Pathak; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Federico Perfetto; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Clin Epigenetics       Date:  2020-11-17       Impact factor: 6.551

3.  Cardiac mechanical efficiency is preserved in primary cardiac hypertrophy despite impaired mechanical function.

Authors:  June-Chiew Han; Kenneth Tran; David J Crossman; Claire L Curl; Parisa Koutsifeli; Joshua P H Neale; Xun Li; Stephen B Harrap; Andrew J Taberner; Lea M D Delbridge; Denis S Loiselle; Kimberley M Mellor
Journal:  J Gen Physiol       Date:  2021-06-28       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.